Celldex Therapeutics ( NASDAQ:CLDX ) Full Year 2022 Results Key Financial Results Net loss: US$112.3m (loss widened by...
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Celldex (CLDX) delivered earnings and revenue surprises of 0% and 62.80%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?